Skip to main content
. 2021 Apr 27;13(9):2108. doi: 10.3390/cancers13092108

Figure 3.

Figure 3

MRD-related incidence of relapse and duration of CR from NILG trial 10/07 in 61 AYA patients aged 10–40 years with Ph− ALL: (Left) cumulative incidence of relapse; and (Right) comparative CR duration in subsets with MRD < 0.01%/10−4 at EOI/Week 4 and Week 10 vs. others (non-significant p value due to small patient number).